EGFR and non-small cell lung carcinoma: In conclusion, our study revealed a profound transcriptomic-metabolomic cellular reprogramming during the early-onset drug escape of EGFR-mutant NSCLC cells against precision therapy, with resultant significant mitochondrial prosurvival priming.